FDA has been asked by Congress to report on adverse events and seizures associated with brand and generic an-tiepileptic drugs. Congress said it wants FDA to examine the pharmacokinetic profiles of antiepileptic drugs that have a therapeutic equivalence evaluation code of "A" and are made by different manufacturers. FDA has until September 30 to submit a report on whether the agency recommends making changes to therntests for bioequivalence.
展开▼
